ArticleCombinatorial chemistry & high throughput screening2026
Novel Benzimidazole-Thiazolidine-2,4-dione Hybrid Compounds as Promising PPAR-γ Modulators with Antidiabetic Activity: Design, Synthesis, Molecular Docking, and
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDesign, synthesis, and molecular docking studies of a novel series of Benzimidazole-Thiazolidine-2,4-dione hybrid compounds as PPAR-γ modulators for antidiabetic activity. Thiazolidinediones function as agonists of PPAR-γ, influencing the expression of numerous genes involved in the regulation of glucose, lipid, and protein metabolism. They improve insulin sensitivity by promoting glucose uptake in adipose tissue and skeletal muscle, and by reducing hepatic gluconeogenesis.
objectivesTo perform the synthesis, molecular docking studies, in vitro cytotoxicity assessment, glucose uptake assay, and
methodsA molecular hybridization strategy was employed for the synthesis of Benzimidazole- Thiazolidine-2,4-dione hybrid compounds, and their chemical identities were confirmed using
resultsSynthesized compounds were screened for their activation potential of PPAR-γ expression in HepG2 cell lines, and several compounds, notably PT14 and PT18, displayed an activation potential higher than the reference standard pioglitazone. DISCUSSION: Compounds PT18 and PT14 exhibited significant PPAR-γ expression in comparison to the commercially available PPAR-γ agonist pioglitazone, at a concentration of 1μM which was used as the benchmark of agonist action.
conclusionCompounds PT14 and PT18 are promising candidates to investigate further, as they exhibit significant cell viability, glucose uptake, and PPAR-γ transcription factor activation in nuclear extracts. These encouraging findings warrant further exploration through in vivo pharmacokinetic and antidiabetic efficacy studies, which will help establish their therapeutic potential and safety profile in biological systems.
Indexed as
Identifiers
40820456What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.